Document is current
Any future updates will be listed below
-
Authors
Peng, JuanFei
Yang, JiaJin
Antonopoulou, Georgia https://orcid.org/0000-0001-9681-4890
Fang, Rui
Adhikari, Bikash https://orcid.org/0000-0002-9064-0356
Vogt, Markus https://orcid.org/0000-0002-4525-2901
Wolf, Elmar https://orcid.org/0000-0002-5299-6335
Sun, Chong https://orcid.org/0000-0001-9008-2158
Du, Shangce
Godfrey, Laura
Gupta, Aayush
Trajkovic-Arsic, Marija
Teichmann, Nicole
Grünwald, Barbara T.
Krebs, Niklas
Steiger, Katja https://orcid.org/0000-0002-7269-5433
Mogler, Carolin https://orcid.org/0000-0003-3400-7254
Althoff, Kristina
Wang, Xin
Giglio, Giovanni https://orcid.org/0009-0009-0349-3756
Liffers, Sven-Thorsten
Savvatakis, Konstantinos
Braren, Rickmer https://orcid.org/0000-0001-6039-6957
Lawlor, Rita T. https://orcid.org/0000-0003-3160-0634
Scarpa, Aldo https://orcid.org/0000-0003-1678-739X
Behrens, Diana
Lang, Karl S.
Cheung, Phyllis F. https://orcid.org/0000-0002-0075-5679
Siveke, Jens T. https://orcid.org/0000-0002-8772-4778
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01KD2206A/SATURN3)
EC | Seventh Framework Programme (602783)
Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen (CANcer TARgeting (CANTAR))
Deutsche Forschungsgemeinschaft (418179183)
Deutsche Forschungsgemeinschaft (421166016)
Deutsche Forschungsgemeinschaft (450917483)
Deutsche Krebshilfe (70115201)
Deutsches Krebsforschungszentrum (DKTK)
Deutsches Konsortium für Translationale Krebsforschung
- License Information
-
More Information
Article History
Received: 9 June 2024
Accepted: 22 January 2026
First Online: 6 February 2026
Competing interests
: J.T.S. receives honoraria as a consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche/Genentech, and Servier. His institution receives research support from Abalos Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisbach Bio, Oncolytics Therapeutics and Roche/Genentech; he holds ownership in FAPI Holding (<3%), all outside the submitted work. The remaining authors declare no competing interests.
